CDMO Selection for Small Molecule vs Biologics
Understanding the key differences when selecting CDMOs for small molecule versus biologic drug development.
1 min read912 viewsPublished September 5, 2025
CDMO Selection for Small Molecule vs Biologics
Small Molecule Considerations
Manufacturing Complexity
- Chemical synthesis routes
- Impurity profiles
- Stability requirements
Equipment Requirements
- Reactors and process equipment
- Purification systems
- Solid dosage capabilities
Biologics Considerations
Manufacturing Complexity
- Cell line development
- Upstream/downstream processing
- Analytical characterization
Specialized Capabilities
- Cell culture expertise
- Chromatography systems
- Cold chain logistics
Comparison Framework
| Criteria | Small Molecule | Biologics |
|----------|---------------|-----------|
| Scale-up | Linear | Non-linear |
| Timeline | 12-18 months | 18-36 months |
| Cost | Lower | Higher |
| Regulatory | Well-established | Evolving |
Was this article helpful?
Sign in to provide feedback